StockNews.AI
A
StockNews.AI
124 days

Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

1. Agilent's PD-L1 assay receives IVDR certification for cancer treatment. 2. This designation may boost demand and market presence for Agilent.

2m saved
Insight
Article

FAQ

Why Bullish?

The IVDR certification enhances Agilent's product portfolio, potentially leading to increased sales. Historical examples show similar certifications often result in stock price upticks for biotech firms.

How important is it?

The news directly enhances Agilent’s competitive positioning in oncology diagnostics, indicating positive future revenue.

Why Short Term?

Initial market response is likely short-term as investors react to regulatory news and its implications for sales.

Related Companies

MRNABMYJNJ
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced.

Related News